Aug. 31 at 12:37 PM
$IBRX This chart is from one of the abstracts to be presented at the upcoming aislc lung conference. In a previous post it was mentioned that the average OS for all patients in the study was 14.3 months but, this included patients who suffered from severe lymphopenia throughout the study.
HOWEVER:
As seen in the chart, the OS for all patient’s who maintained an ALC of >= 1500 (67% of patients), the OS increased to 21.1 months, almost double other treatments! Additionally, 37% of those patients survived 42 months and 20% survived 58 months. Patients using any other treatment would have zero hope of surviving anywhere near that long!
As stated in a summary by ChatGPT:
“Patients with healthy lymphocyte counts (≥ 1,500) lived a median of 21.1 months, nearly double those with severe lymphopenia (11.5 months), and far better than older chemotherapy outcomes (5–7 months). Statistically, keeping lymphocytes up was highly significant (p = 0.0009), reducing death risk by two-thirds.”
